Skip to main content
S&P 5007,754.82-0.60%DOW51,159.56-0.04%NASDAQ27,161.29-1.37%BTC$81,467.00-2.30%ETH$2,447.10-4.49%GOLD$4,150.80+0.24%OIL$91.48+3.62%
Smart Investors Daily
SID Premium
NS

NASDAQ · NSPR

InspireMD, Inc.

Healthcare · Medical - Devices

$0.51

Down-$0.04 (-8.07%)

Updated Oct 8, 2026, 7:02 PM

SID Score

3.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
82.62M
P/E ratio
-3.1
Dividend yield
0.00%
52-week range
$0.50 – $1.98
Volume
145.45K
Avg. volume
128.09K

Price performance · NSPR

NSPR price history

1M range · 0 trading sessions · Daily adjusted prices

NSPR does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest NSPR news

The latest Smart Investors Daily articles mentioning NSPR.

Stock researchCompany · Overview

NSPR research

Overview

Company profile and research snapshot.

Company profile

InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$4.75
Implied upside
—
Analysts
8
NSPR recent ratings
DateFirmRatingTarget
May 5, 2026Piper SandlerOverweight—
May 12, 2025Piper SandlerOverweight—
Dec 11, 2024Lake StreetBuy—
Sep 17, 2024Piper SandlerOverweight—
Nov 2, 2023Piper SandlerOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 21, 2026

InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million

- Amendments align trigger event of existing warrants with anticipated FDA approval of CGuard Prime 80 cm, which the Company continues to anticipate in Q4 2026 - - The amended warrants, if exercised in full, together with existing cash balances, expected to provide additional resources to fund launch of CGuard Prime 80 cm following FDA approval - - No additional warrants issued in connection with the amendments - MIAMI, Sept. 21, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireM

Benzinga · Sep 17, 2026

Full Transcript: InspireMD Q2 2026 Earnings Call

InspireMD (NASDAQ:NSPR) reported second-quarter financial results on Monday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you by Benzinga

Yahoo · Sep 4, 2026

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MIAMI, Sept. 04, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD’s Board of Directors approved inducement grants to a new non-executive employee in the aggregate amount of 23,764 shares of restricted stock (the “Inducement Grants”) outside of InspireMD’s 2021 Equity Incentive Plan, with a grant date as of September

Yahoo · Sep 3, 2026

InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference

MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming H.C. Wainwright 28th Annual Global Investment Conference on Monday, September 14th at 2:30 pm Eastern Time (ET). A live audio webcast and an archive of the recording will be available through the investors page of InspireMD’s corporate website at https://investors

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By